Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. reports developments as a computational chemistry company focused on generative design of small molecules for pharmaceutical and agricultural applications. Its recurring updates center on ChemPass AI™, a proprietary generative AI platform used to explore chemical space and optimize small-molecule candidates across multiple parameters.
Company news also covers financial results, strategic refocusing around ChemPass AI™, collaborations in drug discovery and ag-chemical development, and subsidiary activity. Reported subsidiary themes include Casterra's castor seed varieties and castor farming systems for bio-based industries, AgPlenus work on novel herbicides and fungicides, Biomica microbiome-based therapeutics, and Nasdaq listing-compliance matters for EVGN ordinary shares.
Evogene (NASDAQ/TASE: EVGN) reported first-half 2026 and Q2 2026 results, highlighting its shift to an AI-driven computational chemistry focus for pharma and crop protection. Q2 net loss narrowed to approximately $1.8 million versus $4.7 million in Q2 2025, while first-half net loss remained about $7.7 million year over year.
The company cut its workforce from 117 employees in December 2024 to 38 in August 2026 and expects 2026 cash usage of roughly $8.5–$9.5 million, down from about $14.4 million in 2025 and $20.5 million in 2024. As of June 30, 2026, cash and cash equivalents were approximately $9.3 million, with Q2 cash usage of about $2.1 million.
Revenues fell to roughly $0.7 million in H1 2026 from $2.9 million a year earlier, mainly due to lower Casterra revenues and the end of AgPlenus’ Bayer agreement. Evogene reported six active drug collaborations and expanded its ChemPass AI™ virtual chemical space to about 110 billion molecules. Dividends from Lavie Bio and Biomica totaled approximately $4.25 million to Evogene since 2025.
Evogene (Nasdaq: EVGN) announced that Chairman Nir Nimrodi will participate in the company’s upcoming quarterly results Zoom conference call on Tuesday, August 18, 2026, at 9:00 AM Eastern Time (4:00 PM Israel time). The call will be accessible via advance online registration and a replay will be posted on Evogene’s website.
Evogene (Nasdaq: EVGN) will release its second quarter 2026 financial results on Tuesday, August 18, 2026. The company, which focuses on computational chemistry and generative design of small molecules for pharma and agriculture, will hold a management-hosted Zoom conference call that same day at 9:00 AM Eastern Time (4:00 PM Israel time) to discuss the results.
Investors must register in advance via the provided Veidan Conferencing link, and a replay of the entire conference will be available on Evogene's website a few days after the event.
Evogene (Nasdaq: EVGN) and ELEO announced a strategic scientific collaboration to discover and develop next-generation oral small-molecule inhibitors of the PCSK9 pathway for treating hyperlipidemia and cardiovascular diseases. The collaboration combines Evogene's ChemPass AI™ computational chemistry platform with ELEO's biological capabilities, including target validation, PCSK9 expression suppression models, and screening platforms.
The partners aim to generate, optimize, and experimentally validate novel candidates with improved oral potency, bioavailability, selectivity, and drug-like properties, accelerating advancement toward preclinical development. According to the companies, this targets a PCSK9 inhibitor market projected to grow from about $4.4 billion in 2025 to over $23 billion by 2035, and may support future strategic licensing, clinical development, or pharmaceutical partnerships.
AgPlenus, a subsidiary of Evogene (NASDAQ: EVGN), launched its Antifungal Potency Predictor (APP), a machine-learning model that predicts antifungal potency of small molecules directly from chemical structure. The model expands ChemPass AI for Ag™ by forecasting biological efficacy before synthesis and fungal assays.
According to AgPlenus, APP should reduce the number of molecules needing experimental testing, prioritize candidates with higher probability of success, and accelerate fungicide discovery. It is intended to support AgPlenus’ fungicide pipeline, including target APTF-1, and future programs against pathogens such as Botrytis and Fusarium.
Evogene (Nasdaq:EVGN) and Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) announced a strategic joint initiative to accelerate AI-driven small-molecule drug discovery from Israel's academic ecosystem.
The collaboration combines Evogene's ChemPass AI™ computational chemistry platform with BCDD's experimental infrastructure under an integrated DMTA (Design-Make-Test-Analyze) workflow.
Evogene (NASDAQ: EVGN) announced a major milestone in its second collaboration with Google Cloud, integrating agentic computational systems into its ChemPass AI™ platform. The upgraded engine uses Google's Gemini models and Gemini Enterprise Agent Platform to enable earlier, deeper Target Product Profile (TPP) profiling for small‑molecule discovery.
Autonomous AI agents now integrate structural, biological, chemical and clinical data to define key clinical and biological success criteria at early stages. This is intended to accelerate discovery timelines, improve scalability and help prioritize high‑potential molecules before large R&D investments.
Evogene (NASDAQ: EVGN) will present its pharma division achievements at the BIO International Convention in San Diego, held June 22-25, 2026. The company will highlight AI-driven small-molecule discovery, including its ChemPass AI platform, and management will be available for one-on-one investor meetings.
Evogene (Nasdaq: EVGN) reported successful completion of a first-in-human Phase 1 study of BMC128, a rationally designed live bacterial product, in combination with Nivolumab in 11 patients with advanced solid tumors.
The study met its primary safety endpoint, showed preliminary anti-tumor signals, and supports continued development by licensing partner Lishan Biotech.
Evogene (NASDAQ: EVGN) reported first quarter 2026 revenue of approximately $0.3 million, down from $2.3 million in 2025, and a net loss of about $5.9 million versus $3.0 million a year earlier. Cash, cash equivalents and deposits totaled roughly $13.1 million.
Evogene closed a February 2026 warrant inducement raising around $3.4 million gross and recorded about $3.8 million related financing expenses. Non-core subsidiaries Lavie Bio and Biomica obtained court approvals for dividends, with Evogene expecting roughly $4.25 million combined over 2026.